Ipsen – Monthly information relative to the total number of voting rights and shares composing the share capital
Monthly information relative to the total number of voting rights
and shares composing the share capital
(in accordance with Article L.233-8 II of the French Commercial Code and
Article 223-16 of the General Regulation of the Autorité des Marchés Financiers)
Market: Euronext Paris
ISIN Code: FR 0010259150
LEI: 549300M6SGDPB4Z94P11
| Date | Total number of shares composing the share capital | Total number of voting rights (1) |
| 31 May 2023
|
83,814,526
|
Gross total* of voting rights: 132,207,777 |
| Net total** of voting rights: 131,196,375 |
(1) Existence of a statutory clause imposing an obligation to declare threshold crossing complementary to the one relative to the legal thresholds (Article 10).
* Gross total = total number of voting rights attached to the total number of shares, including the number of shares which benefit of double voting rights and the number of treasury shares. The « Gross total » is used as a basis for the calculation of threshold crossings.
** Net total = total number of voting rights attached to the total number of shares – shares without voting rights.
Attachment
IPSEN – Buy-back programme – Art 5 of MAR – Week 24 – 2023
Ipsen delivered sales growth and margin expansion in 2020 – Focused on executing new strategy and delivering financial objectives in 2021
Ipsen delivers strong sales growth for the first nine months and improves its full-year guidance
Correction: Ipsen announces U.S. FDA submission acceptance of its supplemental New Drug Application for Onivyde regimen in first-line metastatic pancreatic ductal adenocarcinoma
Ipsen announces U.S. FDA submission acceptance of its supplemental New Drug Application for Onivyde regimen in first-line metastatic pancreatic ductal adenocarcinoma
U.S. FDA approves Bylvay® for patients living with cholestatic pruritus due to Alagille syndrome
IPSEN – Buy-back programme – Art 5 of MAR – Week 23 – 2023
Ipsen to present new data on clinical outcomes and patient validation tools from growing rare liver disease portfolio at EASL 2023
Ipsen to present new data on clinical outcomes and patient validation tools from growing rare liver disease portfolio at EASL 2023